Drug treatment of glaucoma focuses on reducing/controlling intraocular pressure and preserving visual function. Given the availability of multiple drug classes—i.e., prostaglandin analogues, beta blockers, alpha agonists, carbonic anhydrase inhibitors, fixed-dose combinations, and parasympathomimetics—and several agents in each class, factors such as efficacy, safety/tolerability, frequency of dosing, and cost often determine the treatment approach. Even with multiple generic drugs available, branded therapies such as Allergan’s Lumigan, Combigan, and Alphagan P and Novartis’s Travatan Z still play an important role in glaucoma treatment. Given the continued use of branded therapies, as well as the entrance of new agents to the market, it is essential to understand physicians’ actual prescribing behavior in the treatment of glaucoma.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world data patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Allergan, Novartis, Pfizer, Valeant, Akorn, Aerie Pharmaceuticals
Key drugs: Lumigan, Travatan Z, Zioptan, Xalatan, Vyzulta, Rhopressa, Combigan, Cosopt PF, Simbrinza, Alphagan P, Azopt, Trusopt, Istalol, Betimol, Betoptic S, Timoptic in Ocudose, Timoptic-XE, generics
Key analysis provided: